Centene to Sell Two Pharmacy Businesses for $2.8 Billion
(Bloomberg) -- Centene Corp. will sell two pharmacy businesses it acquired in recent years to separate buyers for a total of $2.8 billion in the latest steps of a portfolio review under new Chief Executive Officer Sarah London.
The health insurer will divest Magellan Rx to Prime Therapeutics LLC and PantherRx Rare to a group of private equity buyers, according to a statement Thursday. Both businesses were acquired in the last two years under Centene's former CEO, Michael Neidorff. Neidorff died earlier this year soon after stepping down from the role.
Last year Centene took a $1.1 billion charge to resolve claims by several states that the Medicaid insurer inflated pharmacy benefits costs. The divestitures, which are subject to antitrust clearance, are part of Centene's strategy to exit the pharmacy benefit management market directly and consolidate that part of its health plan operations with an outside vendor.
Centene said it would get $2.8 billion from the sales. The purchasers for PantherRx include The Vistria Group, General Atlantic and Nautic Partners. The company acquired Magellan Rx as part of its deal for Magellan Health Inc. that closed in January. It bought PantherRx in December 2020.
The company faced pressure last year from activist investor Politan Capital Management LP, which led to new appointments to its board.
Centene shares fell 1.5% in trading before U.S. markets opened.Â
©2022 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
